Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies

BACKGROUND: The first-line chemotherapy for patients with RAS and BRAF wild-type metastatic colorectal cancer (mCRC) commonly involves cytotoxic regimens, such as FOLFOX and FOLFIRI, combined with epidermal growth factor receptor (EGFR) antibodies. When progression occurs following anti-EGFR antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakatsumi, Hiroshi, Komatsu, Yoshito, Muranaka, Tetsuhito, Yuki, Satoshi, Kawamoto, Yasuyuki, Harada, Kazuaki, Dazai, Masayoshi, Tateyama, Miki, Sasaki, Yusuke, Miyagishima, Takuto, Tsuji, Yasushi, Katagiri, Masaki, Nakamura, Michio, Sogabe, Susumu, Hatanaka, Kazuteru, Meguro, Takashi, Kobayashi, Tomoe, Ishiguro, Atsushi, Muto, Osamu, Shindo, Yoshiaki, Kotaka, Masahito, Ando, Takayuki, Takagi, Ryo, Sakamoto, Naoya, Sakata, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682015/
https://www.ncbi.nlm.nih.gov/pubmed/36439491
http://dx.doi.org/10.3389/fonc.2022.939425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682015/
https://www.ncbi.nlm.nih.gov/pubmed/36439491
http://dx.doi.org/10.3389/fonc.2022.939425

Ejemplares similares